Clinical Trials
3 trialsNCT04073602 2023-12-18
A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer
RemeGen Co., Ltd.
Phase 2 Completed
NCT03809013 2023-11-27
A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer
RemeGen Co., Ltd.
Phase 2 Completed
NCT03507166 2019-08-21
A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer
RemeGen Co., Ltd.
Phase 2 Completed